The potential of breast cancer screening in Europe

Research output: Contribution to journalArticleAcademicpeer-review

33 Citations (Scopus)
59 Downloads (Pure)


Currently, all European countries offer some form of breast cancer screening. Nevertheless, disparities exist in the status of implementation, attendance and the extent of opportunistic screening. As a result, breast cancer screening has not yet reached its full potential. We examined how many breast cancer deaths could be prevented if all European countries would biennially screen all women aged 50 to 69 for breast cancer. We calculated the number of breast cancer deaths already prevented due to screening as well as the number of breast cancer deaths which could be additionally prevented if the total examination coverage (organised plus opportunistic) would reach 100%. The calculations are based on total examination coverage in women aged 50 to 69, the annual number of breast cancer deaths for women aged 50 to 74 and the maximal possible mortality reduction from breast cancer, assuming similar effectiveness of organised and opportunistic screening. The total examination coverage ranged from 49% (East), 62% (West), 64% (North) to 69% (South). Yearly 21 680 breast cancer deaths have already been prevented due to mammography screening. If all countries would reach 100% examination coverage, 12 434 additional breast cancer deaths could be prevented annually, with the biggest potential in Eastern Europe. With maximum coverage, 23% of their breast cancer deaths could be additionally prevented, while in Western Europe it could be 21%, in Southern Europe 15% and in Northern Europe 9%. Our study illustrates that by further optimising screening coverage, the number of breast cancer deaths in Europe can be lowered substantially.

Original languageEnglish
Pages (from-to)406-418
Number of pages13
JournalInternational Journal of Cancer
Issue number2
Publication statusPublished - 15 Jan 2021

Bibliographical note

Funding Information:
We like to thank all data providers and EU‐TOPIA workshop participants for their valuable help, expert inputs and critical feedback in the making of this study. This study is part of the EU‐TOPIA project, funded by the EU‐Framework Programme (Horizon 2020) of the European Commission, project reference 634753. The authors alone are responsible for the views expressed in this manuscript.

Publisher Copyright:
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.


Dive into the research topics of 'The potential of breast cancer screening in Europe'. Together they form a unique fingerprint.

Cite this